Atossa Therapeutics, INC 10-Q quarterly reports

Atossa Therapeutics reported continued net losses and substantial doubt regarding its ability to continue as a going concern, despite advancements in its (Z)-endoxifen clinical trials and a recent capital raise.

Atossa Therapeutics reports a net loss of $9.6 million for Q1 2026, with increased R&D expenses driven by clinical trial activities for its lead candidate, (Z)-endoxifen.

Atossa Therapeutics reported a wider net loss in Q3 2025, driven by increased research and development expenses for its lead breast cancer drug candidate, (Z)-endoxifen, while engaging with the FDA on accelerated regulatory pathways.

Atossa Therapeutics reported an increased net loss in Q2 2025 due to higher research and development expenses, while advancing its lead breast cancer drug candidate, (Z)-endoxifen, through multiple clinical trials.

Atossa Therapeutics reports a net loss of $6.7 million for Q1 2025 while advancing its (Z)-endoxifen clinical programs.

Atossa Therapeutics reported a net loss of $7.2 million for the third quarter of 2024, while highlighting positive preliminary data from its (Z)-endoxifen breast density study.

Atossa Therapeutics reported a net loss of $6.0 million for the second quarter of 2024, while continuing to advance its clinical programs for (Z)-endoxifen.

Atossa Therapeutics, a clinical-stage biopharmaceutical company, reported progress in its (Z)-endoxifen development programs and financial results for the first quarter of 2024.